Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation - GBI Research Reports

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation - GBI Research Reports
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation
Published Nov 01, 2016
61 pages — Published Nov 01, 2016
Price US$ 6,995.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available. Current asthma treatment options are able to provide the majority of patients with a sufficient level of disease control. Additionally, scientific advancements through the development of combination and add-on therapeutics have provided patients with treatments that allow for a greater level of disease control. However, unmet need remains, in the form of patients that do not respond well to current therapeutics or therapeutic combinations. This group of patients accounts for the vast majority of global healthcare costs associated with asthma. Pipeline product development aims to improve upon current therapeutic options and provide options for satisfactory disease control to patients with unmet needs. This is reflected in the high number of products in development, with 287 pipeline products, accounting for just over a third of products within the broader respiratory therapy area pipeline. There are a total of 93 first-in-class pipeline products in development for asthma, representing a substantial 44% of the 212 pipeline products for which there is a disclosed molecular target. A number of these first-in-class pipeline programs appear to have significant potential to strengthen the asthma treatment landscape as well as representing promising commercial opportunities. A large number of first-in-class products in the current asthma pipeline have not previously been involved in licensing or co-development deals. This highlights the significant opportunities in the asthma pipeline, and the many possibilities for high-risk, high-reward investment.

Scope

- Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing
- A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy
- The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target
- Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
- Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.
- Visualize the composition of the asthma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.
- Analyze the asthma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within asthma.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical po

  
Source:
Document ID
GBIHC423MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures32
Executive Summary51
  Biologics and mAbs Growing in Prominence in Asthma Treatment51
  Market Landscape to Grow in Diversity over Coming Years51
  Cytokine and Kinase Targeted Small Molecules and mAbs Dominate First-in-Class Innovation51
  Deals Landscape Offers Significant Investment Opportunities for First-in-Class Products51
The Case for Innovation in the Asthma Market64
  Growing Number of Opportunities for Biologic Products71
  Diversification of Molecular Targets71
  Innovative First-in-Class Product Developments Remain Attractive71
  Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications81
  Sustained Innovation81
  GBI Research Report Guidance91
Clinical and Commercial Landscape1013
  Disease Overview101
  Epidemiology101
  Etiology111
  Pathophysiology111
  Disease Symptoms121
  Diagnosis121
    Disease Prgnosis131
    Assessment of Disease Severity132
  Treatment151
    Quick-Relief Medication151
    ICSs for the Maintenance Treatment of Asthma161
    ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma161
    Add-on Therapies to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma171
    Treatment Algorithm183
  Overview of Marketed Products211
  Current Unmet Need in the Asthma Market221
Assessment of Pipeline Product Innovation2310
  Asthma Pipeline by Molecule Type, Stage of Development and Molecular Target236
  Comparative Distribution of Programs between the Asthma Market and Pipeline by Molecular Target291
  First-in-Class Pipeline Programs Targeting Novel Molecular Targets294
Signaling Network and Innovation Alignment333
  Complexity of Signaling Networks in Asthma331
  First-in-Class Matrix Assessment333
First-in-Class Target Evaluation3610
  Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1361
    Overview of Pipeline Programs Targeting Calcium Release Activated Calcium Channel Protein 1371
  Pipeline Programs Targeting CXC Chemokine Receptors371
    Overview of Pipeline Programs Targeting CXC Chemokine Receptors381
  Pipeline Programs Targeting Spleen Tyrosine Kinase381
    Overview of Pipeline Programs Targeting Spleen Tyrosine Kinase391
  Pipeline Programs Targeting Compliment Component 5a Receptor 1401
    Overview of Pipeline Programs Targeting Compliment Component 5a Receptor 1401
  Pipeline Programs Targeting Interleukin-33411
    Overview of Pipeline Programs Targeting Interleukin-33411
  Pipeline Programs Targeting CC Chemokine Receptor Type 3421
    Overview of Pipeline Programs Targeting CC Chemokine Receptor Type 3421
  Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d431
    Overview of Pipeline Programs Targeting Antigen Presenting Glycoprotein CD1d441
  Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha441
    Overview of Pipeline Programs Targeting Interleukin 4 Receptor Subunit Alpha451
  Conclusion451
Deals and Strategic Consolidations4611
  Industry-Wide First-in-Class Deals461
  Asthma Deals Landscape471
  Licensing Deals482
    Molecule Type501
    Molecular Target502
  Co-development Deals521
    Molecule Type531
    Molecular Target532
  Pipeline Products without Prior Licensing or Co-Development Deal Involvement552
Appendix575
  References572
  Abbreviations591
  Primary Research601
  Contact Us611
  Disclaimer611

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation" Nov 01, 2016. Alacra Store. Mar 28, 2024. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Frontier-Pharma-Asthma-Therapeutics-Cytokine-and-Kinase-Targeted-Small-Molecules-and-mAbs-Increase-Pipeline-Diversity-and-Dominate-First-in-Class-Innovation-2115-742>
  
APA:
GBI Research Reports. (2016). Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Nov 01, 2016. New York, NY: Alacra Store. Retrieved Mar 28, 2024 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Frontier-Pharma-Asthma-Therapeutics-Cytokine-and-Kinase-Targeted-Small-Molecules-and-mAbs-Increase-Pipeline-Diversity-and-Dominate-First-in-Class-Innovation-2115-742>
  
US$ 6,995.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.